NeuroLINCs

NeuroLINCs : Non-invasive IVD test measuring brain-enriched lncRNAs specific to NDs.

Features and benefits

First in class test

for the measurement of brain enriched lncRNAs in peripheral blood.

First test of blood lncRNA biomarkers

for diagnostic of MCI, early Alzheimer and other dementia types.

Investigation of a novel class

of therapeutic targets.

Proprietary list

of brain enriched lncRNAs.

More than 100.000 capture probes

for high coverage of lncRNA sequences.

Provides insights into brain condition

using blood, removing the need for brain biopsies.

Play Video about NeuroLINCs kit

NeuroLINCs provides first class results

to the final users and open new horizons to future therapeutics and precision medicine tools for key applications including diagnostics to detect early cognitive impairment and dementia, as well as drug development.

Simplified workflow

Non-invasively collected samples to investigate lncRNAs.
PAXgene, plasma, brain tissue, PBMCs already validated.
Excellent analytical performance with high reproducibility of the results.
High sensitivity with 5930 lncRNAs detected in PAXgene and 3166 in Plasma over a total of 7494 lncRNAs.

Sample Preparation

Total RNA Extraction

Library Preparation

lncRNAs Capture

Sequencing

using Illumina's cutting-edge NGS platforms

Data analysis

Bioinformatics
the NeuroLINCs kit
the NeuroLINCs kit

Optimize your biomarker projects and development programs

From concept to regulatory qualification, with significant experience in each step, we provide steadfast support across diverse areas

Biomarker design

and analytical validation

Planning and study design

Development of SOPs

Standard Operating Procedures

Regulatory support

preparing dossiers and opinion meeting

Biomarker regulatory qualification

for IVD development

We are committed to improve disease outcome, therapeutic decisions and generate savings in healthcare

through biomarker discovery, development and regulatory qualification.

Contact Us